Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.

Alice Kate Cummings Joyner Julia Thornton SniderSally West WadeSi-Tien WangMarric G BuessingScott J JohnsonUsama Gergis

Published in: Advances in therapy (2022)

Axi-cel is a cost-effective CAR T cell therapy for patients with R/R LBCL compared to tisa-cel and liso-cel. Site of care does not impact the cost-effectiveness of CAR T cell therapy.

Keyphrases

cell therapy
healthcare
palliative care
diffuse large b cell lymphoma
quality improvement
stem cells
acute lymphoblastic leukemia
acute myeloid leukemia
pain management
affordable care act
hodgkin lymphoma
bone marrow